HHS confirmed Friday (Jan. 27) that FDA's meetings to discuss user fee reauthorization with Congress were canceled. A spokesman for HHS told Inside Health Policy the cancellation is intended to allow time for President Donald Trump's administration to meet with current FDA staff. “Because these meetings were dealing with future policy, a decision was made to postpone them in order to give the new administration time to meet with FDA staff and be fully briefed on the policy,” the spokesman...